The tumor inhibition rate of the SFV/IFNg+Pam3 treatment group versus the PBS group was 59.6%, whereas SFV/Luc+Pam3 treatment reached only 27.8% versus the PBS group, indicating the therapeutic activity of IFNg. The gene discussed is IFNG; the disease is neoplasm.